TAF1L (TATA-Box Binding Protein Associated Factor 1 Like)

News alerts, weekly reports and conference planners

7ms

Construction and validation of acetylation-related gene signatures for immune landscape analysis and prognostication risk prediction in luminal breast cancer. (PubMed, Cancer Cell Int)

In this study, we successfully constructed a 6-gene acetylation-associated risk model for luminal breast cancer, providing a new direction and evidence for personalized treatment. Our results also suggested that KAT2B and TAF1L might serve as potential therapeutic targets in luminal breast cancer.

7 months ago

Journal • Gene Signature • BRCA Biomarker • IO biomarker

CD8 (cluster of differentiation 8) • ASPSCR1 (ASPSCR1 Tether For SLC2A4) • LAMP2 (Lysosomal Associated Membrane Protein 2) • TAF1L (TATA-Box Binding Protein Associated Factor 1 Like)

1year

Clinicopathological features and prognostic significance of TAF1L in gastric cancer. (PubMed, BMC Gastroenterol)

TAF1L is closely related to the occurrence and development of GC. Our results suggested that TAF1L is a significant biomarker for predicting prognosis of GC and may play an important role in immunotherapy and targeted therapy.

1 year ago

Journal • IO biomarker

HER-2 (Human epidermal growth factor receptor 2) • TAF1L (TATA-Box Binding Protein Associated Factor 1 Like)

HER-2 positive • MSI-H/dMMR

over2years

Deep molecular profiling of advanced synovial sarcoma as a basis for interventional clinical trials (ESMO 2023)

Comparative analysis of SSTR1, SSTR2, SSTR3, SSTR4, and SSTR5 expression between the SySa cases (n=56) and the entire MASTER cohort (n=3,023) revealed significant differences for SSTR2, SSTR4, and SSTR5, with top 10% expression in 13, 31, and 22 patients, respectively. Conclusions Our study demonstrates the utility of broad molecular profiling in patients with advanced SySa for identifying subgroups of patients, whose molecular profiles may inform the design of future clinical trials.

over 2 years ago

Clinical • Metastases

TP53 (Tumor protein P53) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • SSTR2 (Somatostatin Receptor 2) • SSTR5 (Somatostatin Receptor 5) • SS18 (SS18 Subunit Of BAF Chromatin Remodeling Complex) • TAF1L (TATA-Box Binding Protein Associated Factor 1 Like)

SSTR5 expression • SS18-SSX fusion

over2years

CLDN18 fusions rather than expression is a biomarker related to the efficacy of paclitaxel in patients with ovarian metastasis of gastric cancer (ESMO 2023)

Conclusions We have identified potential biomarkers, including CLDN18, that could predict the efficacy of paclitaxel treatment based on the differential response to treatment. We have also confirmed that CLDN18 fusion is a potential predictive biomarker for paclitaxel treatment response, independent of CLDN18 expression.

over 2 years ago

Clinical

CLDN18 (Claudin 18) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • RHOA (Ras homolog family member A) • SALL4 (Spalt Like Transcription Factor 4) • AFF2 (AF4/FMR2 family member 2) • TAF1L (TATA-Box Binding Protein Associated Factor 1 Like)

paclitaxel

almost3years

Genetic variants of cancer‑associated genes analyzed using next‑generation sequencing in small sporadic vestibular schwannomas. (PubMed, Oncol Lett)

The evaluations identified NF2, SYNE1, IRS2, APC, CIC, SDHC, BRAF, NUMA1, EXT2, HRAS, BCL11B, MAGI1, RNF123, NLRP1, ASXL1, ADAMTS20, TAF1L, XPC, DDB2 and ETS1 as mutated genes. The current study could not draw any new conclusions about the relationship between VS-related hearing loss and gene mutations; however, it did reveal that NF2 was the most frequently mutated gene in small sporadic VS.

almost 3 years ago

Journal • Next-generation sequencing

BRAF (B-raf proto-oncogene) • HRAS (Harvey rat sarcoma viral oncogene homolog) • ASXL1 (ASXL Transcriptional Regulator 1) • IRS2 (Insulin receptor substrate 2) • XPC (XPC Complex Subunit, DNA Damage Recognition And Repair Factor) • ETS1 (ETS Proto-Oncogene 1) • BCL11B (BAF Chromatin Remodeling Complex Subunit BCL11B) • DDB2 (Damage Specific DNA Binding Protein 2) • SDHC (Succinate Dehydrogenase Complex Subunit C) • SYNE1 (Spectrin Repeat Containing Nuclear Envelope Protein 1) • TAF1L (TATA-Box Binding Protein Associated Factor 1 Like)

ASXL1 mutation • NF2 mutation

3years

Screening of Lymphoma Radiotherapy-Resistant Genes with CRISPR Activation Library. (PubMed, Pharmgenomics Pers Med)

The 16 genes screened are potential lymphoma radiotherapy-resistant genes. It was initially determined that the high expression of 8 genes was associated with lymphoma radiotherapy resistance, and these genes could serve as the potential biomarkers for predicting lymphoma radiotherapy resistance or as new targets for therapy.

3 years ago

Journal

AKT3 (V-akt murine thymoma viral oncogene homolog 3) • EEF1A1 (Eukaryotic Translation Elongation Factor 1 Alpha 1) • MELTF (Melanotransferrin) • ATP6AP1 (ATPase H+ Transporting Accessory Protein 1) • TAF1L (TATA-Box Binding Protein Associated Factor 1 Like)

over3years

Genomic analysis of an aggressive case with metastatic intrahepatic mucinous cholangiocarcinoma. (PubMed, Clin J Gastroenterol)

Although he received chemotherapy with the combination of gemcitabine and cisplatin, he had renal failure and discontinued the chemotherapy...Molecular carcinogenesis of IHMC may be distinct from that of ordinary cholangiocarcinoma. Further studies are needed to elucidate the genetic mutations and their functions in IHMC.

over 3 years ago

Journal

ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • EPHA3 (EPH receptor A3) • PIK3C2B (Phosphatidylinositol-4-Phosphate 3-Kinase Catalytic Subunit Type 2 Beta) • SYNE1 (Spectrin Repeat Containing Nuclear Envelope Protein 1) • ADGRB3 (Adhesion G Protein-Coupled Receptor B3) • TAF1L (TATA-Box Binding Protein Associated Factor 1 Like)

BRIP1 mutation

cisplatin • gemcitabine • Teysuno (gimeracil/oteracil/tegafur)